GT Biopharma Inc (GTBP NASDAQ) stock market data APIs
$0.4778
0.01(2.1%)
as of February 27, 2026
Try our APIs with
free plan!
GT Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Prev. Close
0.4778
Open
0.4851
High
0.4854
Low
0.4512
52 wk Range
0.401-3.85
Market Cap
12 740 K
Shares Outstanding
26 652 K
EPS
-0.83
Beta
1.253
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GT Biopharma Inc data using free add-ons & libraries
Get GT Biopharma Inc Fundamental Data
GT Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -6 760 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: -0.51
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GT Biopharma Inc News
New
GT Biopharma Reports Full Year 2025 Financial Results
Phase 1trial evaluating GTB-3650TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating G...
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity InsiderMarket Intelligence Brief – The 2026 economy has hit the wall of physical limits. After a decade of rewarding "potenti...
GT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors
(RTTNews) - GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target B7...
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], d...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
